JP2018502168A - 安定な固体フィンゴリモド剤形 - Google Patents

安定な固体フィンゴリモド剤形 Download PDF

Info

Publication number
JP2018502168A
JP2018502168A JP2017556787A JP2017556787A JP2018502168A JP 2018502168 A JP2018502168 A JP 2018502168A JP 2017556787 A JP2017556787 A JP 2017556787A JP 2017556787 A JP2017556787 A JP 2017556787A JP 2018502168 A JP2018502168 A JP 2018502168A
Authority
JP
Japan
Prior art keywords
fingolimod
dosage form
anionic
pharmaceutically acceptable
sugar alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017556787A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502168A5 (enExample
Inventor
ファンユ リウ
ファンユ リウ
Original Assignee
ハンダ ファーマシューティカルズ エルエルシー
ハンダ ファーマシューティカルズ エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハンダ ファーマシューティカルズ エルエルシー, ハンダ ファーマシューティカルズ エルエルシー filed Critical ハンダ ファーマシューティカルズ エルエルシー
Publication of JP2018502168A publication Critical patent/JP2018502168A/ja
Publication of JP2018502168A5 publication Critical patent/JP2018502168A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017556787A 2015-01-20 2016-01-19 安定な固体フィンゴリモド剤形 Pending JP2018502168A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562105603P 2015-01-20 2015-01-20
US62/105,603 2015-01-20
US201562216100P 2015-09-09 2015-09-09
US62/216,100 2015-09-09
PCT/US2016/013938 WO2016118515A1 (en) 2015-01-20 2016-01-19 Stable solid fingolimod dosage forms

Publications (2)

Publication Number Publication Date
JP2018502168A true JP2018502168A (ja) 2018-01-25
JP2018502168A5 JP2018502168A5 (enExample) 2019-02-28

Family

ID=56417652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017556787A Pending JP2018502168A (ja) 2015-01-20 2016-01-19 安定な固体フィンゴリモド剤形

Country Status (8)

Country Link
US (7) US9925138B2 (enExample)
EP (1) EP3247341A4 (enExample)
JP (1) JP2018502168A (enExample)
CN (1) CN107530301A (enExample)
AU (1) AU2016209466A1 (enExample)
CA (1) CA2974375A1 (enExample)
TW (1) TW201642842A (enExample)
WO (1) WO2016118515A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021181411A (ja) * 2020-05-18 2021-11-25 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016118515A1 (en) * 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
AU2020347662B2 (en) * 2019-09-13 2026-07-09 Meiji Co., Ltd. Solid food and solid milk
IL295007A (en) 2020-01-31 2022-09-01 Nanocopoeia Llc Amorphous nilotinib microparticles and uses thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
AU2021424131B2 (en) * 2021-01-28 2026-08-13 Priothera Limited Methods of treatment with s1p receptor modulators
CN117120037A (zh) * 2021-04-14 2023-11-24 株式会社Lg化学 包含具有受控粒度的鞘氨醇-1-磷酸酯受体激动剂的药物组合物
US12171880B2 (en) * 2022-09-08 2024-12-24 Taiwan Mercury Medical Corporation Metformin tablet for relieving pain and reducing inflammation and manufacturing method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508215A (ja) * 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
JP2014509652A (ja) * 2011-04-01 2014-04-21 ノバルティス アーゲー ２−アミノ−２−［２−（４−オクチルフェニル）エチル］プロパン−１，３−ジオールを含む製剤

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2609912A (en) * 1948-09-16 1952-09-09 Rca Corp Hopper for selectively dispensing tube bases
US4136145A (en) 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
US4760094A (en) 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
US4760093A (en) 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
US4767789A (en) 1986-10-21 1988-08-30 American Home Products Corporation (Del.) Spray dried acetaminophen
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
JP3069458B2 (ja) 1992-01-29 2000-07-24 武田薬品工業株式会社 口腔内崩壊型錠剤およびその製造法
US5298261A (en) 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
KR0155015B1 (ko) 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
US5503846A (en) 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
CA2128820A1 (en) 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5851553A (en) 1993-09-10 1998-12-22 Fuisz Technologies, Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5595761A (en) 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
WO1997024112A1 (en) 1995-12-28 1997-07-10 Yoshitomi Pharmaceutical Industries, Ltd. External preparation
JPH11209277A (ja) 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6027746A (en) 1997-04-23 2000-02-22 Warner-Lambert Company Chewable soft gelatin-encapsulated pharmaceutical adsorbates
FR2766089B1 (fr) 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
DK1001748T3 (da) 1997-07-25 2006-08-21 Alpex Pharma Sa Fremgangsmåde til fremstilling af et granulat, som er egnet til fremstilling af i munden oplöselige tabletter, som kan sönderdeles hurtigt
US5869098A (en) 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US6010719A (en) 1997-09-16 2000-01-04 Universiteit Gent Freeze-dried disintegrating tablets
US6465009B1 (en) 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
ES2237121T3 (es) 1998-07-28 2005-07-16 Takeda Pharmaceutical Company Limited Preparacion solida disgregable rapidamente.
US6016861A (en) 1998-09-04 2000-01-25 Davis; Steven Screen assembly for the rear window of a vehicle
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US6740341B1 (en) 1998-11-25 2004-05-25 Cima Labs Inc. Taste masking rapid release coating system
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US8017150B2 (en) 2002-04-11 2011-09-13 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
CA2707750A1 (en) 2003-04-08 2004-10-21 Novartis Ag Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
WO2005065317A2 (en) 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
WO2008015695A2 (en) 2006-05-15 2008-02-07 Sun Pharmaceutical Industries Limited Inclusion complex of olopatadine and cyclodextrin
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
RU2487703C2 (ru) * 2006-09-26 2013-07-20 Новартис Аг Фармацевтические композиции, включающие модулятор s1р
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
US8470361B2 (en) 2006-12-04 2013-06-25 Orexo Ab Non-abusable pharmaceutical composition comprising opioids
WO2009048993A2 (en) 2007-10-12 2009-04-16 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
CN104788325A (zh) 2008-11-11 2015-07-22 诺华股份有限公司 芬戈莫德的结晶形式
FI20086073A0 (fi) 2008-11-12 2008-11-12 Valtion Teknillinen Pienligandeihin sitoutuvat muunnetut avidiinit
EP2198857A1 (en) 2008-12-19 2010-06-23 Ratiopharm GmbH Oral dispersible tablet
KR20120032538A (ko) 2009-07-24 2012-04-05 라티오팜 게엠베하 핀골리모드 염의 제조 방법
CA2797029A1 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh A method of preparing an oral dosage form comprising fingolimod
EP2560621A1 (en) 2010-04-22 2013-02-27 Ratiopharm GmbH Fingolimod in the form of a solid solution
US20130102683A1 (en) 2010-04-22 2013-04-25 Ratiopharm Gmbh Melt-granulated fingolimod
JP5087747B2 (ja) 2010-07-02 2012-12-05 ジヤトコ株式会社 自動変速機
US8735627B2 (en) 2010-10-28 2014-05-27 Mapi Pharma Ltd. Intermediate compounds and process for the preparation of fingolimod
WO2012070059A1 (en) 2010-11-25 2012-05-31 Shilpa Medicare Limited Fingolimod polymorphs and their processes
EP2702034A4 (en) 2011-04-29 2015-03-25 Reddys Lab Ltd Dr PREPARATION OF FINGOLIMOD AND ITS SALTS
WO2013019872A1 (en) * 2011-08-01 2013-02-07 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
EP2609912A1 (en) * 2011-12-30 2013-07-03 Deva Holding Anonim Sirketi Pharmaceutical combination of fingolimod and nabiximols
US20130308675A1 (en) 2012-05-18 2013-11-21 Smartfield, Inc. Optimum plant canopy temperature
US20140199382A1 (en) * 2013-01-11 2014-07-17 Cadila Healthcare Limited Stable pharmaceutical compositions of an s1p receptor agonist
RU2015137972A (ru) 2013-03-08 2017-04-13 Ф. Хоффманн-Ля Рош Аг Новые производные дигидрохинолин-2-она в качестве ингибиторов альдостеронсинтазы (cyp1 1 b2 или cyp1 1 b1)
WO2016118515A1 (en) * 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
WO2017009754A1 (en) 2015-07-16 2017-01-19 Shilpa Medicare Limited Orally administrable film dosage form containing fingolimod

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508215A (ja) * 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
JP2014509652A (ja) * 2011-04-01 2014-04-21 ノバルティス アーゲー ２−アミノ−２−［２−（４−オクチルフェニル）エチル］プロパン−１，３−ジオールを含む製剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
一般財団法人 日本医薬情報センター（JAPIC） 編集・発行, JAPIC「医療用医薬品集」2014, JPN6019039633, 31 August 2013 (2013-08-31), pages 2293 - 2296, ISSN: 0004271836 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021181411A (ja) * 2020-05-18 2021-11-25 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
JP7503420B2 (ja) 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法

Also Published As

Publication number Publication date
EP3247341A4 (en) 2018-12-19
US20210169793A1 (en) 2021-06-10
US20200163875A1 (en) 2020-05-28
WO2016118515A1 (en) 2016-07-28
EP3247341A1 (en) 2017-11-29
US20180235875A1 (en) 2018-08-23
US9925138B2 (en) 2018-03-27
US20230149302A1 (en) 2023-05-18
CN107530301A (zh) 2018-01-02
US20160206557A1 (en) 2016-07-21
US20250041213A1 (en) 2025-02-06
US10925829B2 (en) 2021-02-23
US20240050365A1 (en) 2024-02-15
US10555902B2 (en) 2020-02-11
AU2016209466A1 (en) 2017-08-10
TW201642842A (zh) 2016-12-16
CA2974375A1 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
US10925829B2 (en) Stable solid fingolimod dosage forms
EP3527200A1 (en) Lenalidomide oral tablet composition
EP3525766A1 (en) Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
JP5974469B2 (ja) 錠剤の製造方法
US20090209587A1 (en) Repaglinide formulations
US20180344648A1 (en) Clobazam tablet formulation and process for its preparation
US20200009093A1 (en) Sodium Ibuprofen Tablets and Methods of Manufacturing Pharmaceutical Compositions Including Sodium Ibuprofen
US11246833B2 (en) Method of producing a granulated composition
AU2012241189A1 (en) Fast Dissolving Solid Dosage Form
WO2026022326A1 (en) P2x3 antagonist formulation
AU2015264861C1 (en) Sodium ibuprofen tablets and methods of manufacturing pharmaceutical compositions including sodium ibuprofen
KR20160140567A (ko) 오셀타미비어 유리염기를 포함하는 약학 조성물
GB2625579A (en) An orally disintegrating tablet containing gabapentin or pharmaceutically acceptable salts thereof and the process of preparing the same
JP2005194225A (ja) 胃内崩壊性錠剤
HK1213783B (en) Sodium ibuprofen tablets and methods of manufacturing pharmaceutical compositions including sodium ibuprofen
CZ23089U1 (cs) Stabilní granulovaná farmaceutická kompozice solifenacinu nebo jeho soli
HK1178076A (en) Sodium ibuprofen tablets and methods of manufacturing pharmaceutical compositions including sodium ibuprofen
BRPI1010748B1 (pt) Composição farmacêutica compreendendo ibuprofeno sódico dihidratado
JP2015061830A (ja) 塩酸アンブロキソールの小型徐放性製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190118

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191029

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200602